Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03324503 · ClinicalTrials.gov registry record · NA
A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis
A NA study, sponsored by Celgene.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT03324503 is a NA study that has completed, run by Celgene. The registered enrollment target is 8 participants.
The verdict
NCT03324503, a NA study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a multicenter, single-arm, unblinded/open-label study of the effect size of HRCT endpoints in response to glucocorticoid induction therapy in subjects with a diagnosis of pulmonary sarcoidosis who have not received glucocorticoid as initial sarcoidosis therapy (≥ 20 mg/day prednisone or prednisolone) or other sarcoidosis therapy for at least 3 months prior to enrollment. This study will enroll a total of approximately 24 subjects.
Interventions
- DRUG Glucocorticoid (prednisone or prednisolone)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-12-08 |
| Est. Completion | 2019-11-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03324503
The ClinicalTrials.gov registry entry for NCT03324503 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Glucocorticoid (prednisone or prednisolone) is the first listed.
NCT03324503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03324503 about?
NCT03324503 is a clinical study titled "A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis". This is a multicenter, single-arm, unblinded/open-label study of the effect size of HRCT endpoints in response to glucocorticoid induction therapy in subjects with a diagnosis of pulmonary sarcoidosis who have not received glucocorticoid as initial sarcoidosis therapy (≥ 20 mg/day prednisone or pred...
What is the current status of trial NCT03324503?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2017-12-08. Estimated completion is 2019-11-15.
What interventions are being tested in trial NCT03324503?
The interventions under investigation include: Glucocorticoid (prednisone or prednisolone) (DRUG).
Who is sponsoring clinical trial NCT03324503?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.